Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Firdapse amifampridine phosphate Lambert-Eaton Myasthenic Syndrome, adults Reimburse with clinical criteria and/or conditions Complete
Lenvima and Keytruda lenvatinib and pembrolizumab advanced or metastatic renal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Minjuvi tafasitamab Diffuse large B-cell lymphoma (DLBCL) Do not reimburse Complete
Albrioza sodium phenylbutyrate and ursodoxicoltaurine Amyotrophic lateral sclerosis (ALS) Reimburse with clinical criteria and/or conditions Complete
Aduhelm aducanumab Alzheimer’s disease Withdrawn
Spinraza nusinersen Spinal Muscular Atrophy Do not reimburse Complete
Wakix pitolisant hydrochloride Narcolepsy Do not reimburse Complete
Vyndaqel tafamidis Transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Withdrawn